International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8300877
Original Article
To Assess Mannheim Peritonitis Index (MPI) In Predicting Complications in Patients Who Presented with Features of Peritonitis
 ,
 ,
 ,
 ,
Published
Aug. 30, 2023
Abstract

Introduction: The purpose of the study was to find the complications in post-operative patients of peritonitis using Mannheim’s Peritonitis index. An observational study conducted in a 60 patiens at tertiary care centre as emergency cases of perforation. Patients with clinical suspicion and investigatory support for the diagnosis of peritonitis (diffuse or localised) due to hollow viscous perforation who are later confirmed by intra- operative findings were included in study. Quantitative data was tested by Mean and Standard Deviation, difference between two means tested by ’Z’ test. Qualitative data was compared by Chi square test, Fisher’s exact test. P value <0.05 was considered significant. Conclusion:  it seems that most peritonitis cases were of non-colonic sepsis origin and presented late I.e. after 24 hours of perforation, had to be managed with exploratory laparotomy and primary Closure. In the present study, recovery rate was 86.67% and death rate was 13.33%. MPI score of <21 was significantly more associated with recovery (p=0.0008) hence we observed more recovery rate, as most of the patients in our study had MPI score of <21. MPI score of >29 was significantly more associated with deaths (p=0.0001), hence we have observed deaths among those patients who had high MPI scores. So MPI (Mannheim Peritonitis Index) can be used for assessing severity and predicting prognosis of the peritonitis patients.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
2974 Views
18 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved